Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has earned an average rating of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the stock in the last year is $327.5556.

Several equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an “overweight” rating in a research report on Friday, June 27th. Wall Street Zen raised shares of BeOne Medicines from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $311.00 to $349.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. JPMorgan Chase & Co. boosted their price target on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th. Finally, TD Securities reissued a “buy” rating and issued a $334.00 price target on shares of BeOne Medicines in a research report on Thursday, April 24th.

BeOne Medicines Stock Up 1.8%

NASDAQ:ONC opened at $304.30 on Friday. The stock has a fifty day simple moving average of $265.25. The firm has a market capitalization of $33.35 billion, a P/E ratio of -81.80 and a beta of 0.27. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. BeOne Medicines has a 52 week low of $158.84 and a 52 week high of $308.87.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, analysts expect that BeOne Medicines will post -5.82 EPS for the current year.

Insiders Place Their Bets

In other news, CEO John Oyler sold 27,802 shares of BeOne Medicines stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $253.38, for a total value of $7,044,470.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Xiaobin Wu sold 1,363 shares of BeOne Medicines stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $354,380.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 143,493 shares of company stock valued at $35,948,388. Corporate insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently made changes to their positions in ONC. Caitong International Asset Management Co. Ltd acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $28,000. Farther Finance Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $39,000. Signaturefd LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $49,000. Parallel Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $59,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $121,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.